Droxidopa

• L-threo- 3 ,4- dihydroxyphenylserine
• L -threo- DOPS
• L- DOPS

Norepinephrine precursor

Template: Infobox chemical / molecular formula search available

Droxidopa is a pro-drug for Parkinson's disease, which is metabolized as they pass the blood -brain barrier to the neurotransmitter norepinephrine. Droxidopa can compensate for a deficiency of noradrenaline in the brain.

Fields of application are the so-called Freezing symptom ( freeze the motion ), dopamine - β - hydroxylase deficiency and orthostatic circulatory regulation disorders.

The active ingredient in 1919 for the first time, at that time, synthesized in the laboratories of the Sumitomo Pharmaceuticals Co. as a racemate. The drug is available in the Japanese market under the trade name DOPS since 1989. Since 2005, Chelsea Therapeutics International tries to obtain a license from the Food and Drug Administration for droxidopa as a remedy for orthostatic hypotension. 2007 droxidopa was declared the orphan drug. In February 2014, the matter has now finally approved in the U.S. as Northera.